Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole-transcriptome sequencing of A549 cells and cisplatin-resistance A549/DPP cells

ABSTRACT: Whole-transcriptome sequencing of A549 cells and cisplatin-resistance A549/DPP cells

PROVIDER: PRJNA603901 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10988650_1.fastq.gz	Fastqsanger.gz
	SRR10988650_2.fastq.gz	Fastqsanger.gz
	SRR10988651.fastq.gz	Fastqsanger.gz
	SRR10988652_1.fastq.gz	Fastqsanger.gz
	SRR10988652_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Whole-transcriptome sequencing of A549 cells and cisplatin-resistance A549/DPP cells

Project description:The aim of this study was to investigate the molecular mechanisms underlying cisplatin 14 (DDP) resistance in non-small cell lung cancer (NSCLC) cells by constructing a competing 15 endogenous RNA (ceRNA) network.

2020-01-31 | GSE144520 | GEO

Transcription profiling of human A549 NSCLC cells cisplatin induced changes

Project description:Affymetrix high-density oligonucleotide microarray analysis was performed to analyse cisplatin-induced gene expression changes in A549 NSCLC cells. Cells were treated with 50 ÂµM of cisplatin for 1 hour and incubated for a further 10 hours in drug-free media before the gene expression changes were investigated. Results show that cisplatin induced changes in the expression of genes involved in apoptosis, cell cycle control, DNA repair and transcription. Experiment Overall Design: Gene expression changes in response to cisplatin were analysed by Microarray technology in A549 NSCLC cells. Cells were treated with 50 ÂµM of cisplatin (or drug-free media) for 1 hour and incubated for a further 10 hours in drug-free media before the cisplatin-induced gene expression changes were investigated. Control and cisplatin-treated samples were collected from three independent experiments.

2008-06-14 | E-GEOD-6410 | biostudies-arrayexpress

Pulsed cisplatin treatment of A549 lung adenocarcinoma cells

Project description:Pulsed cisplatin treatment of A549 lung adenocarcinoma cells

| PRJNA679554 | ENA

Integrated proteomic and global phosphoproteomic analysis of cisplatin-induced apoptosis in A549 cells

Project description:Protein phosphorylation, a widely occurring and significant post-translational modification, is integral to various biological processes. We previously utilized a protein affinity probe to identify genes damaged by cisplatin, revealing that it inflicts substantial damage on protein kinase and protein phosphatase genes. In this study, we investigated cisplatin-induced alterations in the proteome and global phosphoproteome of A549 cells. Employing Fe-IMAC beads and tyrosine phosphorylation enrichment antibodies, we identified 6944 protein groups and 18,274 phosphorylation sites on 4,915 proteins across three biological replicates of both cisplatin-treated A549 cells and control cells. Among these, 730 tyrosine phosphorylation sites were identified—marking the most substantial discovery of such sites in A549 cells following cisplatin treatment. Bioinformatics analysis indicated that the proteins exhibiting significant phosphorylation level changes, which are predominantly involved in RNA processing, modification, transcription, translation, and the spliceosome. This suggests that cisplatin-induced damage to protein kinases and phosphatases may disrupt the normal function of these proteins, consequently impairing DNA replication, RNA translation, and shearing, ultimately culminating in tumor cell death. Moreover, we cross-referenced our proteomic data with our previously obtained cisplatin-damaged genes, observing that the majority of down-regulated proteins derived from cisplatin-induced gene damage.

2024-10-20 | PXD053902 | Pride

Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (miRNA)

Project description:To determine the signaling networks that are dysregulated in cisplatin-resistant non-small cell lung cancer, noncoding RNA expression data were obtained from, and compared between, the lung adenocarcinoma cell line, A549, and its cisplatin-resistant derivative, A549/CDDP. Noncoding RNA expression data from a cisplatin-sensitive lung adenocarcinoma cancer cell line (A549) were collected and compared to noncoding RNA expression data from a cisplatin-resistant cell line (A549/CDDP). 3 independent experiments were completed for both the sensitive and resistant cell lines.

2013-01-15 | E-GEOD-43249 | biostudies-arrayexpress

Pulsed cisplatin treatment of A549 lung adenocarcinoma cells

Project description:A549 lung adenocarcinoma cells were pulsed for 2h with cisplatin and allowed to recover for 3 days. Cells were then FACS sorted based on size and enriched populations analysed for RNAseq.

2021-05-18 | GSE161800 | GEO

Cisplatin-induced gene expression changes in A549 NSCLC cells

2007-12-01 | GSE6410 | GEO

Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (lncRNA and mRNA)

2013-01-15 | E-GEOD-43493 | biostudies-arrayexpress

Key players of cisplatin resistance: towards a systems pharmacology approach

Project description:The cellular transcriptome of untreated and cisplatin-treated A549 non-small cell lung cancer cells and their cisplatin-resistant sub-line A549rCDDP2000 was screened with a whole genome array for gene candidates relevant for cisplatin resistance.

2018-04-17 | GSE108214 | GEO

Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (miRNA)

2013-01-15 | GSE43249 | GEO